Naftazone

Summary

Naftazone (CHEMBL2106794) is an approved small molecule (ATC C05CX02); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C05CX02
• Indications: 1 condition
• Chemistry: 215.21 Da · C11H9N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106794
Name	Naftazone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71688
ATC	C05CX02
Molecular formula	C11H9N3O2
Molecular weight	215.21
InChIKey	AGSIRJFXAANBMW-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)C=CC(=C2O)N=NC(=O)N

IUPAC name: (1-hydroxynaphthalen-2-yl)iminourea

Also known as: Haemostop injection, Karbinon, Mediavan, Mediaven, Naftazona, Naftazone, NAFTAZONE

Patent coverage: 55 distinct patent families (176 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 157 (89%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).